How can you knock an aussie bio with a near approved FDA approved product already generating circa 2 mill per annum in proven overseas markets?
Whilst yes it's not shooting the lights out, we are valued under 300 mill with a revenue generating product that will receive FDA approval in June.
Cu6 and the like are valued in excess of 500 million with phase 3 trials.
We also have acne going into phase 3 and antibiotic arms going into phase 2B.
The market is completely missing this at present. Based on numbers this will push towards the $1bill valuation post FDA approval.
The run to 30 cents begins shortly.
Ann: December 2023 Quarterly Activities Report and Appendix 4C, page-33
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
-0.005(1.75%) |
Mkt cap ! $441.0M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.8¢ | 27.8¢ | $2.808M | 9.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2857 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 77213 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.3¢ |
Change
-0.005 ( 2.72 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 30.5¢ | 27.8¢ | 3452172 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| BOT (ASX) Chart |